Week of March 29th, 2021 | Vol. 10, Issue 13

In This Issue Featured Headlines Recent Industry Transactions Industry Trading Comps Recent Industry Headlines Market Reports Upcoming Events Quick Links Who We Are LinkedIn Corporate Site LinkedIn M&A Discussion Group Daybreak Consumer Care Contact Information Xan Smith Managing Director Business Development xsmith@bourne-partners.com Jeremy C. Johnson Managing Director Head of M&A and Capital Advisory jjohnson@bourne-partners.com

INDUSTRY M&A SNAPSHOT Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.

MARKET REPORTS Recent Materials Providing Insight Into Healthcare Related Industries

Altartis Capital Partners | Perrigo Generic Rx Assets March 2021

ICON | PRA Health Sciences February 2021

Charles River | Cognate Bioservices February 2021

EOY Pharma Services Sector Snapshot January 2021

Current M&A Pipeline Representative Current Retained Sell-Side And Partnering Opportunities

Project Trident Buy-side | Generic Pharma | Manufacturing liquid generics Project Aspen Sell-side | CDMO | Multinational CDMO headquartered in US Project Athena Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse Project Bulldog Sell-side | Pharma Services| Life sciences consulting firm

BioNTech nabs EU approval for former Novartis plant tapped in COVID-19 vaccine production push

On a quest to turn out 2 billion doses of their COVID-19 vaccine Comirnaty this year, Pfizer and BioNTech just scored a major boost thanks to the European approval of a linchpin manufacturing plant in Germany.  BioNTech won a thumbs up from the European Medicines Agency (EMA) to start making and supplying partners with vaccine drug product from the Marburg, Germany facility it picked up from Novartis last fall. The regulator this week cleared BioNTech to manufacture messenger RNA—the vaccine's active ingredient—there, making it one of the largest mRNA production sites globally, BioNTech said in a release. Read more at Fierce Pharma.

RECENT INDUSTRY TRANSACTIONS An Overview of Transactions Within Market Sub-segments Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.

M&A TRANSACTIONS

Pharma & Biotech 18 transactions totaling $525 million Supplies, Equipment & Services 22 transactions totaling $515 million Healthcare IT & Managed Care 8 transactions totaling $110 million Healthcare Facilities & Distributors 10 transactions totaling $21 million

PRIVATE PLACEMENTS

Pharma & Biotech 41 transactions totaling $1,793 million Supplies, Equipment & Services 22 transactions totaling $505 million Healthcare IT & Managed Care 14 transactions totaling $612 million Healthcare Facilities & Distributors 4 transactions totaling $559 million

PUBLIC OFFERINGS

Pharma & Biotech 34 transactions totaling $2,714 million Supplies, Equipment & Services 10 transactions totaling $3,896 million Healthcare IT & Managed Care 1 transaction totaling $250 million Healthcare Facilities & Distributors 4 transactions totaling $2,593 million

INDUSTRY TRADING COMPS A Breakdown of Relevant Trading Multiples Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.

To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors. For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.  Note: data reflects prior week close.

RECENT INDUSTRY TRANSACTIONS A Sampling of Relevant Industry Headlines from Last Week Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.

Everlywell acquires PWNHealth, Home Access Health to expand at-home lab testing services March 25, 2021 - Fierce Healthcare At-home health testing startup Everlywell has acquired PWNHealth and Home Access Health and rebranded the parent company as Everly Health. PWNHealth and Home Access Health offer self-collected lab testing services. The new company, Everly Health, will support more than 20 million people in all 50 U.S. states, Canada and Puerto Rico, according to a company statement. Healthcare 'map maker' Komodo Health nets $220M to build out data analytics March 25, 2021 - Fierce Healthcare The startup has created a massive "healthcare map," an artificial intelligence platform that compiles de-identified healthcare data from hundreds of sources and more than 325 million individual patients. The company offers a real-time view into patient healthcare journeys to help life sciences companies and payers detect disparities in care and identify interventions, the company said. Startup medical supplier Better Health secures $3.5M seed round, partnerships with Humana, Oscar March 25, 2021 - Fierce Healthcare Better Health aims to crack into the $60 billion durable medical equipment market with an e-commerce platform. Its tool provides patients with personalized product recommendations as well as estimates for out-of-pocket costs and handles necessary medical and insurance paperwork. WuXi Bio, busy building out ex-China production network, taps local CDMO for capacity boost March 22, 2021 - Fierce Pharma WuXi Biologics marked 2020 with gung-ho expansions as the China-based CDMO looked to beef up its operations in Europe and the U.S. Now, the company is turning back to its home country with a deal for a homegrown CDMO.

Welcome to Bourne, let's talk. Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.